Drug Profile
LY 2393910
Alternative Names: LY2393910Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Germany (PO, Capsule)
- 09 Jun 2011 Eli Lilly completes its phase I trial for Type-2 diabetes mellitus in Germany (NCT01253278)
- 31 Mar 2010 Phase-I clinical trials in Type-2 diabetes mellitus in Germany (PO)